Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with staphylococcus aureus

Journal of Clinical Microbiology

Volumn 53, Issue 1, 2015, Pages 227-236

  Sharma Kuinkel, Batu K ^a   Wu, Yuling ^b   Tabor, David E ^b   Mok, Hoyin ^b   Sellman, Bret R ^b   Jenkins, Amy ^b   Yu, Li ^b   Jafri, Hasan S ^b   Rude, Thomas H ^a   Ruffin, Felicia ^a   Schell, Wiley A ^a   Park, Lawrence P ^a   Yan, Qin ^a   Thaden, Joshua T ^a   Messina, Julia A ^a   Fowler, Vance G ^a,c   Esser, Mark T ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MEDIMMUNE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; STAPHYLOCOCCUS ALPHA TOXIN; VIRULENCE FACTOR; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; BACTERIUM ANTIBODY; HEMOLYSIN; STAPHYLOCOCCAL ALPHA-TOXIN;

ADULT; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEMODIALYSIS; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; MALE; MIDDLE AGED; SEQUENCE ANALYSIS; SERODIAGNOSIS; STAPHYLOCOCCAL BACTEREMIA; ADOLESCENT; ADVERSE EFFECTS; AGED; ANIMAL; BACTEREMIA; BLOOD; CLASSIFICATION; GENE EXPRESSION; GENETICS; HEMOLYSIS; IMMUNOLOGY; MICROBIOLOGY; POSTOPERATIVE COMPLICATION; RABBIT; RENAL REPLACEMENT THERAPY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; BACTEREMIA; BACTERIAL TOXINS; FEMALE; GENE EXPRESSION; GENETIC VARIATION; GENOTYPE; HEMOLYSIN PROTEINS; HEMOLYSIS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RABBITS; RENAL DIALYSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919473548     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02023-14     Document Type: Article

References (62)

1. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association. Endorsed by the Infectious Diseases Society of America. Circulation 111: e394-e434.
2. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. 2000. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 30:454-460. http://dx.doi.org/10.1086/313710.
3. Wang A, Athan E, Pappas PA, Fowler VG, Jr, Olaison L, Pare C, Almirante B, Munoz P, Rizzi M, Naber C, Logar M, Tattevin P, Iarussi DL, Selton-Suty C, Jones SB, Casabe J, Morris A, Corey GR, Cabell CH. 2007. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 297:1354-1361. http://dx.doi.org/10.1001/jama.297.12.1354.
4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309-317. http://dx.doi.org/10.1086/421946.
5. Hersh AL, Chambers HF, Maselli JH, Gonzales R. 2008. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 168:1585-1591. http://dx.doi.org/10.1001/archinte.168.14.1585.
6. Parker D, Prince A. 2012. Immunopathogenesis of Staphylococcus aureus pulmonary infection. Semin Immunopathol 34:281-297. http://dx.doi.org/10.1007/s00281-011-0291-7.
7. Martin GS, Mannino DM, Eaton S, Moss M. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546-1554. http://dx.doi.org/10.1056/NEJMoa022139.
8. Fowler VG, Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS. 2005. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293:3012-3021. http://dx.doi.org/10.1001/jama.293.24.3012.
9. Miro JM, Anguera I, Cabell CH, Chen AY, Stafford JA, Corey GR, Olaison L, Eykyn S, Hoen B, Abrutyn E, Raoult D, Bayer A, Fowler VG, Jr. 2005. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 41:507-514. http://dx.doi.org/10.1086/431979.
10. Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG, Jr, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falco V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH. 2009. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis Prospective Cohort Study. Arch Intern Med 169:463-473. http://dx.doi.org/10.1001 /archinternmed.2008.603.
11. Jensen AG, Espersen F, Skinhoj P, Rosdahl VT, Frimodt-Moller N. 1997. Increasing frequency of vertebral osteomyelitis following Staphylococcus aureus bacteraemia in Denmark 1980-1990. J Infect 34:113-118. http://dx.doi.org/10.1016/S0163-4453(97)92395-1.
12. Klevens RM, Edwards JR, Andrus ML, Peterson KD, Dudeck MA, Horan TC. 2008. Dialysis surveillance report: National Healthcare Safety Network (NHSN) data summary for 2006. Semin Dial 21:24-28. http://dx.doi.org/10.1111/j.1525-139X.2007.00379.x.
13. Anderson DJ, Arduino JM, Reed SD, Sexton DJ, Kaye KS, Grussemeyer CA, Peter SA, Hardy C, Choi YI, Friedman JY, Fowler VG, Jr. 2010. Variation in the type and frequency of postoperative invasive Staphylococcus aureus infections according to type of surgical procedure. Infect Control Hosp Epidemiol 31:701-709. http://dx.doi.org/10.1086/653205.
14. Tracy LA, Furuno JP, Harris AD, Singer M, Langenberg P, Roghmann MC. 2011. Staphylococcus aureus infections in US veterans, Maryland, USA, 1999-2008. Emerg Infect Dis 17:441-448. http://dx.doi.org/10.3201/eid1703.100502.
15. Brown DR, Pattee PA. 1980. Identification of a chromosomal determinant of alpha-toxin production in Staphylococcus aureus. Infect Immun 30:36-42.
16. Pattee PA, Glatz BA. 1980. Identification of a chromosomal determinant of enterotoxin A production in Staphylococcus aureus. Appl Environ Microbiol 39:186-193.
17. Fairweather N, Kennedy S, Foster TJ, Kehoe M, Dougan G. 1983. Expression of a cloned Staphylococcus aureus alpha-hemolysin determinant in Bacillus subtilis and Staphylococcus aureus. Infect Immun 41: 1112-1117.
18. Otto M. 2010. Basis of virulence in community-associated methicillinresistant Staphylococcus aureus. Annu Rev Microbiol 64:143-162. http://dx.doi.org/10.1146/annurev.micro.112408.134309.
19. Wilke GA, Bubeck Wardenburg J. 2010. Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular injury. Proc Natl Acad Sci U S A 107:13473-13478. http://dx.doi.org/10.1073/pnas.1001815107.
20. Chua KY, Monk IR, Lin YH, Seemann T, Tuck KL, Porter JL, Stepnell J, Coombs GW, Davies JK, Stinear TP, Howden BP. 2014. Hyperexpression of alpha-hemolysin explains enhanced virulence of sequence type 93 community-associated methicillin-resistant Staphylococcus aureus. BMC Microbiol 14:31. http://dx.doi.org/10.1186/1471-2180-14-31.
21. Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, DeLeo FR, Chambers HF, Lu Y, Otto M. 2009. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U S A 106:5883-5888. http://dx.doi.org/10.1073/pnas.0900743106.
22. Bubeck Wardenburg J, Bae T, Otto M, Deleo FR, Schneewind O. 2007. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 13:1405-1406. http://dx.doi.org/10.1038/nm1207-1405.
23. Bubeck Wardenburg J, Patel RJ, Schneewind O. 2007. Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect Immun 75:1040-1044. http://dx.doi.org/10.1128/IAI.01313-06.
24. Bubeck Wardenburg J, Schneewind O. 2008. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205:287-294. http://dx.doi.org/10.1084/jem.20072208.
25. Spaulding AR, Salgado-Pabon W, Merriman JA, Stach CS, Ji Y, Gillman AN, Peterson ML, Schlievert PM. 2014. Vaccination against Staphylococcus aureus pneumonia. J Infect Dis 209:1955-1962. http://dx.doi.org/10.1093/infdis/jit823.
26. Patel AH, Nowlan P, Weavers ED, Foster T. 1987. Virulence of protein A-deficient and alpha-toxin-deficient mutants of Staphylococcus aureus isolated by allele replacement. Infect Immun 55:3103-3110.
27. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. 2010. Targeting of alphahemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 202:1050-1058. http://dx.doi.org/10.1086/656043.
28. Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J. 2012. ADAM10 mediates vascular injury induced by Staphylococcus aureus alpha-hemolysin. J Infect Dis 206:352-356. http://dx.doi.org/10.1093/infdis/jis192.
29. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, Datta V, Ren S, Feng H, Zinsou R, Keller A, O'Day T, Du Q, Cheng L, Damschroder M, Robbie G, Suzich J, Stover CK, Sellman BR. 2014. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother 58:1108-1117. http://dx.doi.org/10.1128/AAC.02190-13.
30. DeLeo FR, Otto M. 2008. An antidote for Staphylococcus aureus pneumonia? J Exp Med 205:271-274. http://dx.doi.org/10.1084/jem.20080167.
31. Ohlsen K, Lorenz U. 2010. Immunotherapeutic strategies to combat staphylococcal infections. Int J Med Microbiol 300:402-410. http://dx.doi.org/10.1016/j.ijmm.2010.04.015.
32. Mocca CP, Brady RA, Burns DL. 2014. Role of antibodies in protection elicited by active vaccination with genetically inactivated alpha-hemolysin in a mouse model of Staphyloccocus aureus skin and soft tissue infections. Clin Vaccine Immunol 21:622-627. http://dx.doi.org/10.1128/CVI.00051-14.
33. Ragle BE, Bubeck Wardenburg J. 2009. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 77:2712-2718. http://dx.doi.org/10.1128/IAI.00115-09.
34. Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, Woods R, Barnes A, MacGill RS, Wilson S, Chowdhury P, Stover CK, Sellman BR. 2012. Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol 19:377-385. http://dx.doi.org/10.1128/CVI.05589-11.
35. Caballero A, Foletti D, Bierdeman M, Tang A, Arana A, Hasa-Moreno A, Sangalang E, O'Callaghan RJ. 2014. Effectiveness of alpha-toxin Fab monoclonal antibody therapy in limiting the pathology of Staphylococcus aureus keratitis. Ocul Immunol Inflamm 9:1-7. http://dx.doi.org/10.3109 /09273948.2014.920035.
36. Adhikari RP, Ajao AO, Aman MJ, Karauzum H, Sarwar J, Lydecker AD, Johnson JK, Nguyen C, Chen WH, Roghmann MC. 2012. Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis 206: 915-923. http://dx.doi.org/10.1093/infdis/jis462.
37. Campbell SJ, Deshmukh HS, Nelson CL, Bae IG, Stryjewski ME, Federspiel JJ, Tonthat GT, Rude TH, Barriere SL, Corey R, Fowler VG, Jr. 2008. Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. J Clin Microbiol 46:678-684. http://dx.doi.org/10.1128/JCM.01822-07.
38. Fowler VG, Jr, Nelson CL, McIntyre LM, Kreiswirth BN, Monk A, Archer GL, Federspiel J, Naidich S, Remortel B, Rude T, Brown P, Reller LB, Corey GR, Gill SR. 2007. Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection. J Infect Dis 196:738-747. http://dx.doi.org/10.1086/520088.
39. Mathema B, Mediavilla J, Kreiswirth BN. 2008. Sequence analysis of the variable number tandem repeat in Staphylococcus aureus proteinAgene: spa typing. Methods Mol Biol 431:285-305.
40. Ewing B, Hillier L, Wendl MC, Green P. 1998. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 8: 175-185.
41. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, Lin F, Lin J, Carleton HA, Mongodin EF, Sensabaugh GF, Perdreau-Remington F. 2006. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 367:731-739. http://dx.doi.org/10.1016/S0140-6736(06)68231-7.
42. Dall'Acqua WF, Kiener PA, Wu H. 2006. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:23514-23524. http://dx.doi.org/10.1074/jbc.M604292200.
43. Sharma-Kuinkel BK, Ahn SH, Rude TH, Zhang Y, Tong SY, Ruffin F, Genter FC, Braughton KR, Deleo FR, Barriere SL, Fowler VG, Jr. 2012. Presence of genes encoding Panton-Valentine leukocidin is not the primary determinant of outcome in patients with hospital-acquired pneumonia due to Staphylococcus aureus. J Clin Microbiol 50:848-856. http://dx.doi.org/10.1128/JCM.06219-11.
44. Kernodle DS, McGraw PA, Barg NL, Menzies BE, Voladri RK, Harshman S. 1995. Growth of Staphylococcus aureus with nafcillin in vitro induces alpha-toxin production and increases the lethal activity of sterile broth filtrates in a murine model. J Infect Dis 172:410-419. http://dx.doi.org/10.1093/infdis/172.2.410.
45. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. 2007. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 195:202-211. http://dx.doi.org/10.1086/510396.
46. Tkaczyk C, Hamilton MM, Datta V, Yang XP, Hilliard JJ, Stephens GL, Sadowska A, Hua L, O'Day T, Suzich J, Stover CK, Sellman BR. 2013. Staphylococcus aureus alpha toxin suppresses effective innate and adaptive immune responses in a murine dermonecrosis model. PLoS One 8:e75103. http://dx.doi.org/10.1371/journal.pone.0075103.
47. NIBSC-HPA. 2010. The 3rd international standard for Staphylococcus alpha antitoxin, equine NIBSC code: STA. National Institute for Biological Standards and Control, p 1-4. National Institute for Biological Standards and Control. Potters Bar, Hertfordshire, United Kingdom.
48. Ruotsalainen E, Karden-Lilja M, Kuusela P, Vuopio-Varkila J, Viro-lainen-Julkunen A, Sarna S, Valtonen V, Jarvinen A. 2008. Methicillinsensitive Staphylococcus aureus bacteraemia and endocarditis among injection drug users and nonaddicts: host factors, microbiological and serological characteristics. J Infect 56:249-256. http://dx.doi.org/10.1016/j.jinf.2008.01.009.
49. Deleo FR, Kennedy AD, Chen L, Wardenburg JB, Kobayashi SD, Mathema B, Braughton KR, Whitney AR, Villaruz AE, Martens CA, Porcella SF, McGavin MJ, Otto M, Musser JM, Kreiswirth BN. 2011. Molecular differentiation of historic phage-type 80/81 and contemporary epidemic Staphylococcus aureus. Proc Natl Acad Sci U S A 108:18091-18096. http://dx.doi.org/10.1073/pnas.1111084108.
50. Larinkari U. 1982. Serum antibody to staphylococcal teichoic acid and alpha-haemolysin in dermatological patients. Br J Dermatol 107:53-58. http://dx.doi.org/10.1111/j.1365-2133.1982.tb00289.x.
51. Fritz SA, Tiemann KM, Hogan PG, Epplin EK, Rodriguez M, Al-Zubeidi DN, Bubeck Wardenburg J, Hunstad DA. 2013. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin Infect Dis 56:1554-1561. http://dx.doi.org/10.1093/cid/cit123.
52. Bronner S, Monteil H, Prevost G. 2004. Regulation of virulence determinants in Staphylococcus aureus: complexity and applications. FEMS Microbiol Rev 28:183-200. http://dx.doi.org/10.1016/j.femsre.2003.09.003.
53. Delaune A, Dubrac S, Blanchet C, Poupel O, Mader U, Hiron A, Leduc A, Fitting C, Nicolas P, Cavaillon JM, Adib-Conquy M, Msadek T. 2012. The WalKR system controls major staphylococcal virulence genes and is involved in triggering the host inflammatory response. Infect Immun 80:3438-3453. http://dx.doi.org/10.1128/IAI.00195-12.
54. Monecke S, Muller E, Buchler J, Stieber B, Ehricht R. 2014. Staphylococcus aureus in vitro secretion of alpha toxin (hla) correlates with the affiliation to clonal complexes. PLoS One 9:e100427. http://dx.doi.org/10 .1371/journal.pone.0100427.
55. Vuong C, Kocianova S, Yao Y, Carmody AB, Otto M. 2004. Increased colonization of indwelling medical devices by quorum-sensing mutants of Staphylococcus epidermidis in vivo. J Infect Dis 190:1498-1505. http://dx .doi.org/10.1086/424487.
56. Oganesyan V, Peng L, Damschroder MM, Cheng L, Sadowska A, Tkaczyk C, Sellman BR, Wu H, Dall'Acqua WF. 2014. Mechanisms of neutralization of a human anti-alpha toxin antibody. J Biol Chem 289: 29874-29880. http://dx.doi.org/10.1074/jbc.M114.601328.
57. Colque-Navarro P, Jacobsson G, Andersson R, Flock JI, Mollby R. 2010. Levels of antibody against 11 Staphylococcus aureus antigens in a healthy population. Clin Vaccine Immunol 17:1117-1123. http://dx.doi.org/10 .1128/CVI.00506-09.
58. Verkaik NJ, Dauwalder O, Antri K, Boubekri I, de Vogel CP, Badiou C, Bes M, Vandenesch F, Tazir M, Hooijkaas H, Verbrugh HA, van Belkum A, Etienne J, Lina G, Ramdani-Bouguessa N, van Wamel WJ. 2010. Immunogenicity of toxins during Staphylococcus aureus infection. Clin Infect Dis 50:61-68. http://dx.doi.org/10.1086/648673.
59. Bernardo K, Pakulat N, Fleer S, Schnaith A, Utermohlen O, Krut O, Muller S, Kronke M. 2004. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 48:546-555. http://dx.doi.org/10.1128/AAC.48.2.546-555.2004.
60. Doss SA, Tillotson GS, Amyes SG. 1993. Effect of sub-inhibitory concentrations of antibiotics on the virulence of Staphylococcus aureus. J Appl Bacteriol 75:123-128. http://dx.doi.org/10.1111/j.1365-2672.1993 .tb02756.x.
61. Gemmell CG, Ford CW. 2002. Virulence factor expression by Grampositive cocci exposed to subinhibitory concentrations of linezolid. J Antimicrob Chemother 50:665-672. http://dx.doi.org/10.1093/jac/dkf192.
62. Ohlsen K, Ziebuhr W, Koller KP, Hell W, Wichelhaus TA, Hacker J. 1998. Effects of subinhibitory concentrations of antibiotics on alpha-toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 42:2817-2823.